bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Quest Diagnostics (NYSE:DGX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Institutional and Insider Ownership
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 2.4% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
bioAffinity Technologies has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Profitability
This table compares bioAffinity Technologies and Quest Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -278.90% | -293.44% | -160.36% |
| Quest Diagnostics | 9.53% | 16.21% | 7.41% |
Valuation & Earnings
This table compares bioAffinity Technologies and Quest Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $6.16 million | 0.57 | -$14.91 million | ($44.27) | -0.04 |
| Quest Diagnostics | $11.04 billion | 2.56 | $992.00 million | $10.04 | 25.55 |
Quest Diagnostics has higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for bioAffinity Technologies and Quest Diagnostics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Quest Diagnostics | 0 | 5 | 3 | 1 | 2.56 |
Quest Diagnostics has a consensus price target of $248.70, indicating a potential downside of 3.04%. Given Quest Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Quest Diagnostics is more favorable than bioAffinity Technologies.
Summary
Quest Diagnostics beats bioAffinity Technologies on 13 of the 14 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection. The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services.
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
